30th Jun 2008 12:35
Stem Cell ScienceS
("Stem Cell Sciences", "SCS")
CHANGE OF ADVISER
Date 30 June 2008
Stem Cell Sciences plc (AIM:STEM, ASX:STC), a leading provider of cells and cell culture media to the global pharmaceutical, biopharmaceutical and research markets, announced today that with immediate effect it has appointed Daniel Stewart & Company plc as its Nominated Adviser and Broker.
ENDS
For further information, please contact:
Stem Cell Sciences plc (United Kingdom)
Giorgio Reggiani (Company Secretary)
+44 (0)1223 499160
Daniel Stewart & Company plc
Simon Leathers, Simon Starr
+44 (0)20 7776 6550
Halsin Partners (United Kingdom)
Michael Sinclair, Director
+44 (0) 20 7084 5955
Talk Biotech (Australia)
Fay Weston, Director
+61 (0)422 206 036
Notes to Editors
Stem Cell Sciences plc (SCS, AIM:STEM, ASX:STC) specialises in developing and commercialising technologies to grow, differentiate and purify embryonic, neural and other tissue-specific stem cells. Our patented technologies, proprietary cells, and automated processes and services provide pharmaceutical and biotechnology companies with industrial-scale resources to accelerate drug discovery programmes and regenerative medicine therapies.
Stem Cell Sciences has multiple industry collaborations, including Millipore Corporation for the marketing and distribution of HEScGRO™, its serum free media for the growth of human embryonic stem cells, Merck & Co for the use of mouse neural stem cell technology for research applications and a collaboration in diabetes research with a major pharmaceutical company.
The company is headquartered in Cambridge, UK, in a new, fully equipped cell culture facility featuring state of the art automation for cell culture, with business offices in California (USA) and a research operation in Australia. For further information on the company please visit: www.stemcellsciences.com.
Related Shares:
SThree